Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Walgreens Commits $2.3 Mil. To Settle Pseudoephedrine Sale Complaint

This article was originally published in The Tan Sheet

Executive Summary

Walgreens agreed to a $1.3 mil. fee July 28 to settle government allegations that the company had violated state and federal laws regulating the sale of pseudoephedrine

You may also be interested in...

Combat Meth Act Heads To Senate Floor Without Federal Preemption Clause

The Senate Judiciary Committee unanimously passed the Combat Meth Act of 2005 (S 103) July 28 after adopting an amendment that strikes the federal preemption provision from the bill

Retailers Put Pseudoephedrine Behind Counters, Lend Weight To Talent Bill

A wave of decisions from leading OTC drug retailers to place pseudoephedrine solids behind the counter could provide momentum for a federal pseudoephedrine BTC bill

Pseudoephedrine Tablets Go Behind The Counter In Oklahoma

Legislation restricting the sale of pseudoephedrine tablets to licensed pharmacies was signed into law in Oklahoma on April 7 and is being considered by other states looking to adopt similar measures





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts